How Antibiotics Work: Mechanisms, Classes, Resistance, and the Threat of Superbugs

What Are Antibiotics?

Antibiotics are a class of antimicrobial agents used to treat bacterial infections. They work by either killing bacteria (bactericidal) or inhibiting their growth and reproduction (bacteriostatic), allowing the immune system to clear the infection. Antibiotics are derived from natural sources (fungi, bacteria) or synthesized chemically, and are among the most important medicines ever developed.

Since Alexander Fleming discovered penicillin in 1928 — noticing that the mold Penicillium notatum produced a substance that killed surrounding bacteria on a culture plate — antibiotics have saved hundreds of millions of lives and transformed the practice of medicine. Routine surgeries, cancer chemotherapy, organ transplantation, and premature birth care would be impossible or far more dangerous without effective antibiotics.

However, the accelerating global crisis of antibiotic resistance — bacteria evolving mechanisms to evade antibiotics faster than new drugs are developed — is one of the most serious public health threats of the 21st century. This article is for educational purposes. Antibiotics require medical prescription; never self-medicate or use antibiotics for viral infections.

Why Antibiotics Only Work on Bacteria (Not Viruses)

Antibiotics target structures or processes unique to bacterial cells — structures that human cells do not possess, or that differ enough structurally to allow selective targeting. Viruses are not cells: they are protein-coated nucleic acids that hijack host cell machinery to replicate. They lack the bacterial cell wall, ribosomes, and metabolic machinery that antibiotics target. This is why antibiotics are completely ineffective against viral infections (flu, common cold, COVID-19, most sore throats).

Major Mechanisms of Antibiotic Action

1. Cell Wall Synthesis Inhibitors

Bacterial cells (unlike human cells) have a rigid cell wall made of peptidoglycan — a mesh-like polymer essential for maintaining cell shape and osmotic stability. Antibiotics that block peptidoglycan synthesis cause the cell wall to weaken and rupture as the bacterium tries to grow.

• Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams): Bind to penicillin-binding proteins (PBPs), blocking the cross-linking of peptidoglycan chains. The most widely used antibiotic class.
• Glycopeptides (vancomycin): Bind directly to peptidoglycan precursors, preventing their incorporation. Used for serious Gram-positive infections, including MRSA.

2. Protein Synthesis Inhibitors

Bacterial ribosomes (70S) differ structurally from human ribosomes (80S), allowing selective inhibition.

• Aminoglycosides (gentamicin, streptomycin): Bind 30S ribosomal subunit; cause misreading of mRNA; bactericidal
• Tetracyclines: Block tRNA binding to 30S subunit; broad spectrum; bacteriostatic
• Macrolides (erythromycin, azithromycin): Bind 50S subunit; block translocation; bacteriostatic; widely used for respiratory infections
• Chloramphenicol: Binds 50S subunit; inhibits peptide bond formation; reserved for severe infections due to toxicity
• Linezolid: Binds 50S subunit; active against many drug-resistant Gram-positives

3. DNA/RNA Synthesis Inhibitors

• Fluoroquinolones (ciprofloxacin, levofloxacin): Inhibit DNA gyrase and topoisomerase IV — enzymes essential for DNA replication and repair. Bactericidal; broad spectrum.
• Rifamycins (rifampicin): Inhibit bacterial RNA polymerase; key component of tuberculosis treatment regimens.

4. Membrane Disruption

• Polymyxins (colistin): Disrupt the outer membrane of Gram-negative bacteria; reserved for last-resort treatment of extensively drug-resistant infections due to nephrotoxicity.
• Daptomycin: Disrupts the cell membrane of Gram-positive bacteria.

5. Metabolic Pathway Inhibitors

• Sulfonamides and trimethoprim: Inhibit sequential steps in folate synthesis, a pathway essential for bacterial nucleotide synthesis. Humans obtain folate from diet; bacteria must synthesize it — enabling selective targeting.

Antibiotic Resistance: A Global Emergency

The WHO has declared antimicrobial resistance (AMR) one of the top ten global public health threats. In 2019, AMR was directly responsible for approximately 1.27 million deaths globally and associated with 4.95 million deaths — surpassing HIV/AIDS and malaria as a cause of death, according to a 2022 Lancet study.

How Resistance Develops

Resistance arises through natural selection: when bacteria are exposed to an antibiotic, susceptible bacteria die while any bacteria with resistance mutations survive and reproduce. Bacteria can develop resistance through:

• Enzymatic inactivation: Producing enzymes that destroy or modify the antibiotic. Beta-lactamases degrade penicillins; Extended-Spectrum Beta-Lactamases (ESBLs) degrade most beta-lactams.
• Target modification: Mutating the antibiotic's target so it is no longer recognized. Methicillin-resistant Staphylococcus aureus (MRSA) produces a modified PBP2a that penicillins cannot bind.
• Efflux pumps: Membrane proteins that actively pump antibiotics out of the bacterial cell.
• Reduced permeability: Mutations reducing the number of porin channels through which antibiotics enter the cell.

Horizontal Gene Transfer: How Resistance Spreads

Critically, bacteria can share resistance genes with other bacteria — even of different species — through horizontal gene transfer, particularly via plasmids (small circular DNA molecules). A resistance gene can spread from one bacterial strain to many others far faster than evolutionary mutation alone. This is why resistance to a new antibiotic can emerge and spread globally within years of the antibiotic's introduction.

Key Resistant Pathogens

Combating Resistance: Stewardship and New Approaches

• Antibiotic stewardship: Using narrowest-spectrum antibiotic that works; completing prescribed courses; avoiding antibiotics for viral infections
• Agricultural reform: ~70% of antibiotics globally are used in livestock for growth promotion — a major resistance driver now restricted in the EU and increasingly regulated elsewhere
• Phage therapy: Using bacteriophages (viruses that infect bacteria) to treat infections; highly specific; not affected by antibiotic resistance; in experimental use for some last-resort cases
• New antibiotic development: The antibiotic pipeline is thin — few major new classes have been introduced since the 1980s because development is expensive and unprofitable. Public-private partnerships and new incentive models are attempting to address this market failure.